Journal
IMMUNITY
Volume 50, Issue 4, Pages 924-940Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2019.03.024
Keywords
-
Categories
Funding
- European Research Council [340176]
- MINECO I+D Retos 2017 [SAF2017-86782-R]
- Fundacion BBVA
- World Wide Cancer Research [WWCR 19-0005]
- AGAUR [2017 SGR698]
- Association Espanola de Investigation contra el Cancer (AECC)
- NIH [R01-CA34610, P01-CA94060, P01-CA129243, U54-CA209975, U2C-CA233284, P30-CA008748]
- Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center at MSKCC
- European Research Council (ERC) [340176] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Transforming growth factor (TGF)-beta is a crucial enforcer of immune homeostas's -Ind tolerance, inhibiting the expansion and function of many components of the immune system. Perturbations in TGF-beta signaling under-lie inflammatory diseases and promote tumor emergence. TGF-beta is also central to immune suppression within the tumor microenvironment, and recent studies have revealed roles in tumor immune evasion and poor responses to cancer immunotherapy. Here, we present an overview of the complex biology of the TGF-beta family and its context-dependent nature. Then, focusing on cancer, we discuss the roles of TGF-beta signaling in distinct immune cell types and how this knowledge is being leveraged to unleash the immune system against the tumor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
